Biomarker-integrated Approach Used to Evaluate NSCLC Therapies

Share this content:
Researchers found that MK-2206 plus AZD6244 (selumetinib) improves progression-free survival of patients with a KRAS mutation.
Researchers found that MK-2206 plus AZD6244 (selumetinib) improves progression-free survival of patients with a KRAS mutation.

Using a biomarker-integrated approach to evaluate various therapies in previously treated patients with advanced non-small cell lung cancer (NSCLC), researchers found that MK-2206 plus AZD6244 (selumetinib) improves progression-free survival of patients with a KRAS mutation.1

The Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial previously established the use of real-time biopsy, biomarker-based, adaptively randomized studies in NSCLC. Researchers conducted the BATTLE-2 umbrella study to evaluate the effects of targeted therapies, particularly in patients with advanced, KRAS­-mutant disease.

Investigators enrolled 200 patients with advanced NSCLC who did not have sensitizing EGFR mutations or ALK gene fusions. All participants were refractory to at least 2 prior therapies and 27% had KRAS-mutant tumors.

Patients were randomly assigned to receive erlotinib (arm 1), erlotinib plus the AKT inhibitor MK-2206 (arm 2), MK-2206 plus the MEK inhibitor AZD6244 (arm 3), or sorafenib (arm 4). Tumor gene expression profiling–targeted next-generation sequencing was also used to assess predictive and prognostic biomarkers.

Among the 186 evaluable patients, the 8-week disease control rate was 32% for erlotinib, 50% for erlotinib plus MK-2206, 53% for MK-2206 plus AZD6244, and 46% for sorafenib. The overall disease control rate was 48%.

Among patients with KRAS-mutant tumors, the disease control rate was 20%, 25%, 62%, and 44%, compared with 36%, 57%, 49%, and 47% in patients with KRAS wild-type tumors for arms 1, 2, 3, and 4, respectively.

RELATED: Erlotinib May be Efficacious in Pretreated Advanced Non-small Cell Lung Cancer

Researchers also observed a significant difference in median progression-free survival between arms, with therapies not containing erlotinib resulting in improved progression-free survival in KRAS mutation-positive patients (P = .04).

Despite these findings, the authors note that better biomarker-driven treatment strategies are still needed.                          


  1. Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 study: A biomarker-integrated targeted therapy study in previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol. 2016 Aug 1. doi: 10.1200/JCO.2015.66.0084 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs